Toolgen Inc. and Geneditbio Ltd. struck a strategic cross-license to jointly advance next-generation in vivo genome-editing therapeutics. The deal covers development of editing platforms intended for direct in vivo delivery and aims to combine Toolgen’s editing technologies with Geneditbio’s proprietary assets to accelerate therapeutic candidates toward clinical development. The agreement illustrates growing industry focus on in vivo editing as companies seek to overcome delivery and specificity challenges. Partnerships like this can de-risk preclinical programs, pool IP, and expedite IND-enabling work; competitors will watch for candidate disclosures and clinical plans emerging from the alliance.